Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageBoston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. As a medical technology leader for more than 45 years, we have advanced the practice of less-invasive medicine by helping physicians and other medical professionals diagnose and treat a wide range of diseases and medical conditions and improve patients’ quality of life by providing alternatives to surgery and other medical procedures that are typically traumatic to the body.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Business segments
Q2 2026 · $3.43BThe company’s own SEC segment disclosure.
- Electrophysiology EP$606.0M18%
- Interventional Cardiology Therapies$586.0M17%
- Global Urology and Pelvic Health Reporting Unit$503.0M15%
- Global Endoscopy Endo Reporting Unit$491.0M14%
- Watchman$459.0M13%
- Cardiac Rhythm Management$349.0M10%
- Other (2)$432.0M13%
Boston Scientific (BSX) reported revenue of $5.44B in Q2 2026 (quarter ended June 30, 2026), up 7.5% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $905M (17% of revenue). For the full year FY2025, revenue was $20.1B (+20% year on year) and net income $2.89B. Its largest product in 2026-Q2 was Electrophysiology EP at $606M, 18% of the disclosed total, just ahead of Interventional Cardiology Therapies at 17%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Devices
Ranks #24 of 35 by Smart Score